Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study

Tzu-Tsen Kuo,1,2 Yaw-Bin Huang,1 Ching-Jung Hsieh3

ABSTRACT
Objective We examined the use of cholesterol-lowering drugs in Taiwan in high-risk patients before and after the release of the 2013 American College of Cardiology and the American Heart Association (ACC/AHA) cholesterol guidelines.

Design Retrospective observational study.

Setting Kaohsiung Chang Gung Memorial Hospital database, Kaohsiung City, Taiwan.

Participants Outpatients aged ≥20 years with hypercholesterolaemia and diabetes.

Primary and secondary outcome measures Data on brand and generic names, use and dosage of cholesterol-lowering drugs in 2012 and 2015 were compiled and the total amount used was calculated. Differences in usage and market share were compared. Usage rates of single and fixed-dose combination (FDC) products were compared.

Results The number of patients receiving ambulatory care increased from 36 367 in 2012 to 41 807 in 2015. Single (3 679 979–4 568 086 tablets) and FDC (540 522–572 954 tablets) product use increased from 2012 to 2015, respectively. Statins were the most commonly prescribed medications in 2012 (71.14%) and 2015 (72.91%). The average monthly consumption of statin among high-risk patients in 2012 was 269 948.8 tablets, and it increased significantly to 343 975.3 tablets in 2015. The average monthly consumption of pitavastatin was 34 113.4 tablets in 2015, which was significantly higher than 0 in 2012. Conversely, the highest decline was observed for fluvastatin use, with the average monthly consumption being 38 754.3 tablets in 2015, which was significantly lower than 45 929.8 tablets consumed in 2012. Regarding FDC therapy for cholesterol-lowering drugs, Vytorin (ezetimibe 10 mg + simvastatin 20 mg) use was the highest among all FDCs in 2015.

Conclusions The 2013 ACC/AHA cholesterol guidelines likely promoted the use of fixed-dose, high-intensity and moderate-intensity monotherapy and FDC therapy statins in high-risk groups, and this was consistent with the use of high-intensity or moderate-intensity statins in the present study. Furthermore, these changes were associated with increased effectiveness and reduced adverse effects.

INTRODUCTION
In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) published guidelines for clinical hypercholesterolaemia treatment, recommending new therapeutic approaches for coronary artery disease (CAD) involving primary and secondary preventions. These guidelines recommend the use of fixed-dose, high-intensity and moderate-intensity HMGCR (3-hydroxy-3-methylglutaryl-coenzyme-A [CoA] reductase) inhibitors (statins) to decrease cholesterol levels in high-risk patients with CAD. Treatment with moderate-intensity...
Cholesterol Treatment Trialists, a decrease in LDL-C of those with <5% 10-year ASCVD risk.1

years without DM and LDL-C level of 70–189 mg/dL. The fourth group consisted of patients aged 40–75 years with DM, hypertension and renal disease are ranked second, fourth, fifth, eighth and ninth leading causes of death, respectively, with cardiovascular disease accounting for 31.2% of total mortality.3

Data on the direct association between CAD and hypercholesterolaemia further encourage use of cholesterol-lowering drugs. Regardless of primary or secondary prevention, a very low LDL-C is associated with a low incidence of coronary heart disease (CHD) events.4 In the Cholesterol Treatment Trialists, a decrease in LDL-C of 1 mM reduced CHD risk by 22%.6

Use of cholesterol-lowering drugs has significantly increased since the 2013 revision of the guidelines.4–10 However, data on this trend in Taiwan have not been published. In November 2013, the ACC/AHA cholesterol guidelines relating to high-risk groups defined the effect of cholesterol treatment in cardiovascular events, but it is unclear how these guidelines influenced different cholesterol-lowering drug use in Taiwan. Thus, we aimed to explore the trend in cholesterol-lowering drug use before and after the release of the ACC/AHA cholesterol guidelines.

METHODS

Data source

In this retrospective observational study, data were obtained from the electronic database of Kaohsiung Chang Gung Memorial Hospital for 2012 and 2015. The number of patients using cholesterol-lowering drugs was estimated on the basis of drug consumption rate. The encounter form consisted of patient identification code, diagnostic information indicating the reason for high-risk designation, diagnostic code and drug prescription. Drug information included monthly and annual prescriptions, brand and generic names, dosages, and prescription dates. The electronic database focused on the annual use of drugs in four pharmaceutical drug categories (supplemental table S1) and presented single and fixed-dose combination (FDC) products.

Study population

Data of individuals with familial hypercholesterolaemia, DM, CAD, stroke and PAD designated as high-risk patients, who were prescribed cholesterol-lowering drugs, were compiled. The number of patients enrolled was 36,367 in 2012 and 41,807 in 2015. The inclusion criteria were (1) presence of ASCVD, (2) familial hypercholesterolaemia, (3) DM and (4) aged ≥20 years. Patients with cancer or without medical records were excluded. The remainder comprised patients who received cholesterol-lowering drugs at least once during the study period. Drug information was used to extract distribution data from the electronic database that contained all cholesterol-lowering drug prescription records.

Assessment indicators

We calculated the total quantity and variety of cholesterol-lowering drugs used on a monthly basis, and items with the same ingredient were selected to estimate the total monthly amount of each drug dispensed (see online supplemental table S1). We calculated the annual consumption of all cholesterol-lowering drugs by product class. For cholesterol-lowering drug composition data, the frequency of consumption of Vytorin (ezetimibe + simvastatin at either 10 or 20 mg), Linicor (lovastatin + niacin) and Caduet (amlodipine + atorvastatin) was evaluated. The monthly consumption rate of various individual cholesterol-lowering drugs and FDCs in 2012 and 2015 was calculated. The monthly mean (average monthly consumption of the year) and market share (the percentage of the market for a product or service that a company supplies) of the cholesterol-lowering drugs were calculated and analysed in terms of relative changes between 2012 and 2015. The analysed drug categories were statins, niacin, cholesterol absorption inhibitors and fibrates. Cholesterol-lowering drugs were categorised according to prescription patterns and divided into single or FDC oral cholesterol-lowering drugs (see online supplemental table S1). The drugs were further classified and evaluated according to their respective treatment patterns.

We identified 2398 patients who started statin monotherapy for type 2 DM and who received at least one prescription for statin monotherapy between 1 February 2007 and 9 September 2013; 1633 of these patients were followed up for 1 year until 31 December 2015. The patients were prescribed 10 mg atorvastatin, 80 mg fluvastatin XL, 10 mg rosuvastatin, 40 mg atorvastatin, 2 mg pitavastatin, 40 mg simvastatin or Caduet 5/10 (5 mg amlodipine + 10 mg atorvastatin). The assessment indicators for effectiveness were high-density lipoprotein cholesterol (HDL-C), LDL-C, total cholesterol (TC) and triglyceride levels. Patients were assessed for myopathy,
myalgia, myositis, rhabdomyolysis, cognitive impairment, peripheral neuropathy, headache, and dyspepsia.

**Statistical analysis**

Descriptive statistics were applied to calculate the amount and market share of single and FDC cholesterol-lowering drugs and the relative differences in these rates between 2012 and 2015. Student’s t-test was used to compare the average monthly cholesterol-lowering drug consumption rate during both years of the study, and the mean±SD of continuous variables was calculated. HDL-C, LDL-C, TC, myopathy, myalgia, myositis, rhabdomyolysis, cognitive impairment, peripheral neuropathy, headache, and dyspepsia were compared using McNemar’s test. All analyses were performed using SPSS V.21. Differences were regarded as statistically significant at p<0.05.

The patients were not involved in the planning, design, recruitment and conduct of the study. The results will be disseminated to the study participants directly (in person). This is an observation study and not a randomised controlled trial.

**RESULTS**

The age and sex distribution of the patients are shown in table 1.

| Variable | 2012 | 2015 | \( F/\chi^2 \) | P value |
|----------|------|------|----------------|--------|
| Age, n (mean±SD) | 36,367 (69.2±11.9) | 41,807 (67.2±11.9) | 569.9 | <0.001 |
| Sex, n (%) | | | 4.2 | 0.039 |
| Female | 16,824 (46.3) | 19,032 (45.5) | | |
| Male | 19,543 (53.7) | 22,775 (54.5) | | |

**Table 1** Age and sex distribution of patients

**Table 2** Monthly quantity and market share of cholesterol-lowering drug classes in 2012 and 2015

| Mean monthly quantity and market share | 2012 | 2015 | P value |
|----------------------------------------|------|------|--------|
| HMG-CoA reductase inhibitors, tablets/month (%) | 269,948.8±19,340.3 (71.14) | 343,975.3±34,612.5 (72.91) | <0.001 |
| Fibrates, tablets/month (%) | 73,243.2±4972.8 (19.30) | 79,711.3±6391.4 (16.89) | 0.011 |
| Cholesterol absorption inhibitors, tablets/month (%) | 36,243.0±3644.9 (9.55) | 43,098.8±5095.6 (9.13) | 0.001 |
| Niacin, tablets/month (%) | – | 50,240.0±5162.0 (1.06) | 0.006 |
| Atorvastatin, tablets/month (%) | 68,032.3±4772.6 (22.18) | 84,406.8±7321.5 (22.17) | <0.001 |
| Rosuvastatin, tablets/month (%) | 94,952.6±6657.1 (30.96) | 121,829.9±9972.9 (32.00) | <0.001 |
| Simvastatin, tablets/month (%) | 15,990.6±1301.6 (5.21) | 12,100.8±1120.0 (3.18) | <0.001 |
| Pitavastatin, tablets/month (%) | – | 34,113.4±7507.4 (8.96) | <0.001 |
| Fluvastatin, tablets/month (%) | 45,929.8±3298.2 (14.98) | 38,754.3±2844.0 (10.18) | <0.001 |
| Ezetimibe, tablets/month (%) | 8,516.4±636.8 (2.78) | 9,757.5±1095.6 (2.56) | 0.003 |
| Fenofibrate, tablets/month (%) | 38,069.8±2429.4 (12.41) | 40,854.9±3085.2 (10.73) | 0.022 |
| Gemfibrozil, tablets/month (%) | 35,173.3±3056.0 (11.47) | 38,856.3±3437.9 (10.21) | 0.011 |

Means±SD represents the number of patients receiving a particular cholesterol-lowering drug in 1 month.

HMG-CoA, 3-hydroxy-3-methylglutaryl- coenzyme-A.

**Consumption rate of each class of drug based on cholesterol-lowering drug treatments for high-risk groups**

The average monthly consumption rate of statin, fibrate, cholesterol absorption inhibitor and niacin tablets was significantly higher in 2015 than in 2012 (p=0.011, p=0.001, p=0.001 and p=0.006, respectively; **table 2**). Statins were prescribed more often than all other drugs, accounting for 71.14% and 72.91% of the market share in 2012 and 2015, respectively. Overall, cholesterol-lowering drug use substantially increased in all high-risk groups, with a 1.27-fold increase in statins (see online supplemental figure S1). Although the average statin use increased in 2015, fluvastatin consumption gradually declined. In 2012, niacin was not used, but its market share had increased to 1.06% in 2015. Cholesterol absorption inhibitors showed the second highest increase during the study period, and the increase in ezetimibe use alone accounted for 18.10% of the total increase in this drug class (439,161 tablets in 2012 and 517,186 tablets in 2015). Fibrate consumption showed the third highest increase from 2012 to 2015, accounting for 7.91% of the total increase in 2015 (878,918 tablets in 2012 and 956,535 tablets in 2015).

**Cholesterol-lowering drug treatment for high-risk groups**

The use of single-ingredient products including atorvastatin, ezetimibe, fenofibrate, pitavastatin, fluvastatin, gemfibrozil, rosuvastatin and simvastatin was analysed (**figure 1**). The average monthly consumption of cholesterol-lowering drugs, including atorvastatin (p<0.001), rosuvastatin (p<0.001), simvastatin (p<0.001), pitavastatin (p<0.001), fluvastatin (p<0.001), ezetimibe (p<0.003), fenofibrate (p=0.022) and gemfibrozil (0.011), in high-risk groups was significantly different between 2015 and 2012 (**table 2**). Rosuvastatin and atorvastatin accounted for the highest consumption rates among all.
the studied drugs in 2015 (>1 million tablets or capsules) (rosuvastatin: 1461959 tablets; atorvastatin: 1012881 tablets). The use of all these drugs increased except that of fluvastatin and simvastatin, which was significantly lower in 2015 than in 2012 (p<0.001 each; simvastatin: 15 990.6 tablets in 2012 and 12 100.8 tablets in 2015; fluvastatin: 45 929.8 tablets in 2012 and 38 754.3 tablets in 2015). However, the percentage of market shares of all drugs decreased during this period, except for rosuvastatin and pitavastatin.

The use of rosuvastatin 10 mg (2 531 345 tablets) was 36.1 times higher than that of rosuvastatin 5 mg (70 045 tablets). Its therapeutic doses were classified as high intensity (20–40 mg) and moderate intensity (5–10 mg). Atorvastatin 10 mg use increased by nearly two times that of atorvastatin 40 mg. The consumption of simvastatin 40 mg decreased from 191 887 tablets in 2012 to 145 209 tablets in 2015 as its market share dropped from 5.21% to 3.18%, respectively. Conversely, ezetimibe 10 mg use increased as its market share dropped from 2.78% to 2.56%. In 2012, rosuvastatin (1 139 431 tablets), atorvastatin (816 388 tablets) and fluvastatin (551 158 tablets) were consumed at the highest rates. By 2015, the three most highly used drugs were rosuvastatin (1 461 959 tablets), atorvastatin (1012881) and fenofibrate (490259). Similar to atorvastatin use, rosuvastatin use was high in 2012 (1 139 431 tablets), and it increased further in 2015 (1 461 959).

**Cholesterol-lowering FDC treatments for high-risk groups**

In 2012 and 2015, the main FDCs used were Linicor, Vytorin (ezetimibe 10 mg + simvastatin 10 mg, ezetimibe 10 mg + simvastatin 20 mg) and Caduet. Table 3 shows the monthly average FDC use and their market shares. The usage rate of Vytorin (ezetimibe 10 mg + simvastatin 10 mg) and Caduet in 2015 was significantly lower than that in 2012 (p=0.001; table 3). FDCs accounted for 12.81% of all cholesterol-lowering drugs used in 2012 and 12.17% in 2015. In 2012, Linicor was not prescribed, and its market share was 9.52% in 2015. In 2012, the market shares of Vytorin (ezetimibe 10 mg + simvastatin 10 mg) and Caduet were 1.31% and 38.44%, respectively, which were higher than 0.48% and 27.30% in 2015, respectively. The consumption of the FDC amlodipine 5 mg + atorvastatin 10 mg decreased as its market share dropped from 38.44% to 27.30%, and it affected the usage of the individual constituents. Although use of atorvastatin 10 mg and 40 mg increased, their market shares slightly decreased from 22.18% to 22.17%.

Consumption of the FDC ezetimibe 10 mg + simvastatin 10 mg decreased as its market share dropped from 1.31% to 0.48%. In contrast, in 2012, the market shares of Linicor and Vytorin (ezetimibe 10 mg + simvastatin 20 mg) were 0% and 60.24%, respectively, which were lower than 9.52% and 62.71% in 2015, respectively. Linicor use was ranked third among FDCs, yielding a market share of 9.52%.

In our data set, niacin use showed the least increase, as Linicor was unavailable in the study hospital before 2015. The consumption of ezetimibe 10 mg and simvastatin 10 mg declined more than that of the other FDCs. However, ezetimibe 10 mg and simvastatin 20 mg are suitable for high-intensity use in high-risk groups. Therefore, their consumption has gradually increased (figure 2).

**Table 3** Monthly quantity and market share of fixed-dose combination of cholesterol-lowering drugs in 2012 and 2015

| Drug 2012                                      | 2015                                      | P value |
|------------------------------------------------|-------------------------------------------|---------|
| Linicor (lovastatin 20 mg + niacinER 500 mg)/tablet, tablets/month (%) | –                  | 5024.0±5162.0 (9.52) | 0.006 |
| Vytorin (ezetimibe 10 mg + simvastatin 10 mg)/tablet, tablets/month (%) | 590.6±111.0 (1.31) | 251.3±77.0 (0.48) | <0.001 |
| Vytorin (ezetimibe 10 mg + simvastatin 20 mg)/tablet, tablets/month (%) | 27 136.0±3047.0 (60.24) | 33 090.0±4139.0 (62.71) | 0.001 |
| Caduet 5/10 (amlodipine 5 mg + atorvastatin 10 mg)/tablet, tablets/month (%) | 17 316.9±2349.2 (38.44) | 14 404.8±1228.9 (27.30) | 0.001 |

Mean±SD represents the number of patients receiving a given drug each year.
Effectiveness and adverse effects before and after treatment with statins for 1 and 2 years in patients with diabetes

In terms of effectiveness, HDL-C, LDL-C, TC and triglyceride levels in the 2398 patients treated with statins for a year showed significant improvements (all p<0.001). The probability of myalgia, myositis, rhabdomyolysis, peripheral neuropathy, headache and dyspepsia was not significant. The incidence of myopathy and cognitive impairment was 0.

Significant improvements in HDL-C, LDL-C, TC and triglyceride levels were observed in the 1633 patients treated with statin for 2 years (all p<0.001). These patients also showed a significant probability of myalgia (p=0.004) and myositis (p=0.004) whereas the probability of rhabdomyolysis (p=1.000), peripheral neuropathy (p=1.000), headache (p=0.581) and dyspepsia (p=0.500) was not significant. The incidence of myopathy and cognitive impairment was 0.

Regarding effectiveness, the probability of HDL-C (p=0.016), LDL-C (p<0.001) and TC (p=0.027) levels in the 1633 patients treated continuously with statin for 1 year was significant. Changes in triglyceride level in the 1633 patients treated continuously with statin for 1 year were not significant (p=0.576).

Regarding adverse effects, the resultant changes in myalgia and myositis were significant (each p=0.008). The resultant probability of rhabdomyolysis, peripheral neuropathy, headache and dyspepsia (p=1.000) was not significant. The incidence of myopathy and cognitive impairment was 0.

DISCUSSION

The 2013 ACC/AHA cholesterol guidelines most strongly affected patients 40–75 years of age who did not accept baseline treatments, but began receiving statins for primary ASCVD prevention. Although patients received statins at baseline (LDL-C <80 or <150 mg/dL), their relative risk reductions remained the same. Taiwan followed the recommendations in the 2013 ACC/AHA cholesterol guidelines in treating patients with LDL-C level of ≥100 mg/dL. This is primarily owing to the refusal of the National Health Insurance to approve treatments for patients with LDL-C level below 100 mg/dL, unless they have a cardiovascular disease or diabetes. The contribution of the National Health Insurance to cholesterol-lowering drugs was eventually broadened to include patients with cardiovascular disease or diabetes and put into effect on 1 August 2013. However, in the past, drug treatment was contingent on a TC level of ≥130 mg/dL. This is primarily owing to the refusal of the National Health Insurance to approve treatments for patients with LDL-C level below 100 mg/dL, unless they have a cardiovascular disease or diabetes. The contribution of the National Health Insurance to cholesterol-lowering drugs was eventually broadened to include patients with cardiovascular disease or diabetes and put into effect on 1 August 2013. However, in the past, drug treatment was contingent on a TC level of ≥130 mg/dL. Currently, patients with TC ≥160 mg/dL or LDL-C ≥100 mg/dL can receive treatments. Physicians can also evaluate the conditions of patients to decide if drug cessation is appropriate. Although the market share of niacin has increased, the market shares of the other drug classes have decreased, suggesting that cholesterol-lowering drug consumption is not as consistent as previously reported.

Vytornin (ezetimibe 10 mg + simvastatin 20 mg) use was the highest of all FDCs in 2015. The consumption of simvastatin 10 mg in FDC has declined, whereas that of simvastatin 20 mg has increased (ezetimibe 10 mg + simvastatin 20 mg: 17 316.9 tablets in 2012 and 33 090.0 in 2015; ezetimibe 10 mg + simvastatin 20 mg: 27 136.0 tablets in 2012 and 33 090.0 in 2015). Collectively, the overall consumption of these three FDCs increased, which affected the use of their individual constituents. The introduction of the aforementioned FDCs in the study hospital affected the consumption rate of both their individual constituents and the other FDCs. The FDCs ezetimibe 10 mg + simvastatin 10 mg and ezetimibe 10 mg + simvastatin 20 mg were introduced on 9 March 2007 and 30 December 2008, respectively, whereas simvastatin 40 mg, ezetimibe 10 mg and atorvastatin 10 mg were introduced on 4 November 2004, 22 March 2006 and 22 February 2001, respectively. The consumption of ezetimibe 10 mg + simvastatin 20 mg increased as its market share increased from 60.24% to 62.71%. The introduction of the FDC lovastatin 20 mg + niacin ER 500 mg led to a decrease in the use of the FDC amlodipine 5 mg + atorvastatin 10 mg (lovastatin 20 mg + niacin ER 500 mg: 0 tablets in 2012 and 5024.0 tablets in 2015; amlodipine 5 mg + atorvastatin 10 mg: 17 316.9 tablets in 2012 and 14 404.8 tablets in 2015) with a reduction in its market share from 38.44% to 27.30%. Although the consumption of simvastatin 40 mg decreased as its market share dropped from 5.21% to 3.18% (15 990.6 tablets in 2012 and 12 100.8 in 2015), ezetimibe 10 mg use increased, although its market share dropped from 5.21% to 3.18% (15 990.6 tablets in 2012 and 12 100.8 in 2015).
found a 25% overall increase in statin use in 2014 and a 68% decline in the consumption of non-statin cholesterol-lowering drugs. However, their methodology differed from ours in using OptumRx pharmacy notices for baseline values to determine the number of patients who could start or switch to statin therapy according to the 2013 ACC/AHA cholesterol treatment guidelines. Because the timeframe of 1 January–31 December 2013 is the newly released 2013 ACC/AHA cholesterol treatment guide, there was no buffer period.

The administration of cholesterol absorption inhibitors showed the second highest increase. The lack of definitive cardiovascular benefit had previously limited the widespread adoption of ezetimibe. However, patients with genetic mutations such as Niemann-Pick C1 like 1 (NPC1L1) and HMGCR are especially affected by ezetimibe use in terms of LDL-C and cardiovascular risk reduction. As a considerable proportion of the Taiwanese population carry these mutations, ezetimibe is likely to be of use in this region. Fibrate use in the treatment of dyslipidaemia has significantly changed recently. Fibrate use showed the third highest increase from 2012 to 2015.

Trials of niacin and fibrate reported no significant reduction in cardiovascular events. In our data set, the increase in niacin use was the least. The data reported by Tran et al. were inconsistent with these findings.

We found that following the release of the 2013 ACC/AHA cholesterol guidelines, there was a significant decrease in use of simvastatin and fluvastatin and an increase in use of other statins. Rosuvastatin and atorvastatin may account for the highest consumption rates among all studied drugs in 2015 (>1 million tablets or capsules). In 2012, the consumption rate of rosuvastatin, atorvastatin and fluvastatin was the highest among all cholesterol-lowering drugs, but by 2015 the three most highly used drugs were rosuvastatin, atorvastatin and fenofibrate. Atorvastatin presented the second highest consumption rate, although its market share decreased between 2012 and 2015. The branded and generic forms of atorvastatin became available on 1 October 1997 and 18 July 2010, respectively, whereas generic rosuvastatin appeared in the market on 9 April 2012. Because the expiry of the best-selling drug patent is an important driving force for the growth of the generic drug market, it results in increased generic product use. This may explain the observed increase in atorvastatin and rosuvastatin use. Atorvastatin 10 mg (which is considered a moderate dose when prescribed by physicians) use was two times higher than atorvastatin 40 mg use. Renal clearance is generally lower for atorvastatin, making it a better choice for renal dysfunction. Atorvastatin in primary prevention is related to LDL-C, which has a similar extent of effect in global and Asian populations, and it may be advisable to use it at low doses.

Similar to atorvastatin, rosuvastatin use was high in 2012 and increased further by 2015. The rosuvastatin level in plasma is significantly higher in Asians than in Caucasians; therefore, rosuvastatin dosage often differs slightly between these populations. This may explain why the use of rosuvastatin 10 mg was greater than that of rosuvastatin 5 mg. Here, pitavastatin usage increased the most, at least partially because it had recently been added to the hospital after the release of the revised ACC/AHA guidelines. In the study hospital, pitavastatin 2 mg tablets (Livalo) have been prescribed since 5 July 2013, while Pitator has been administered since 7 November 2014. Although pitavastatin is the newest member of the HMGCR inhibitor family, there were no significant differences in the favourable effects on lipid parameters between pitavastatin and atorvastatin. However, pitavastatin has been associated with increased HDL-C level.

Pitavastatin undergoes minimal metabolism by the cytochrome P450 (CYP) enzymes. Therefore, it has a low propensity for interaction with drugs metabolised by the CYP enzymes. Thus, it provides a clear benefit for patients administered multiple drugs simultaneously. Unlike other statins in this study, single simvastatin 40 mg pill use rapidly decreased.

Simvastatin consumption was considerably lower in 2015, possibly due to its recognised risk for myopathy and rhabdomyolysis. Fluvastatin consumption also considerably decreased, possibly because it is a low-intensity and short-acting statin with poorer performance than other options.

Similar to statins, fibrate consumption also increased with time, with fenofibrate and gemfibrozil ranked the fifth and fourth most highly consumed cholesterol-lowering drugs, respectively. Fibrates may be combined with statins to treat mixed dyslipidaemia. Fenofibrate interacts with statins more effectively than gemfibrozil. The latter is associated with a relatively higher risk of inducing rhabdomyolysis.

Cholesterol-lowering drugs used in FDC were simvastatin 10 mg with ezetimibe 10 mg, simvastatin 20 mg with ezetimibe 10 mg, and atorvastatin 10 mg with anmlodipine 5 mg. The consumption of ezetimibe 10 mg and simvastatin 10 mg declined more than the other FDCs. The consumption of simvastatin 10 mg in FDC has declined, whereas that of simvastatin 20 mg has increased. Ezetimibe 10 mg and simvastatin 20 mg are suitable for high-intensity use in high-risk groups. These drugs lower the LDL-C level more effectively in combination than as monotherapy. However, when ezetimibe is combined with simvastatin, the cost may increase. Therefore, it is easy to cross the 50% LDL-C threshold to meet this standard. Linicor use was ranked third among FDCs. Linicor is a single-pill combination of lovastatin and niacin which reduces LDL-C, increases HDL-C and improves mixed dyslipidaemia, with fewer adverse effects than immediate-release niacin. However, compared with high-intensity drugs, its effect in decreasing LDL-C is poor. Nonetheless, it is cost-effective for patients in Taiwan with health insurance, as it is available at only $10.90 per capsule, which may explain its increased usage.

Although lovastatin is not administered alone because of its short half-life in blood circulation, it cannot be
strictly defined as FDC because the other components enhance the efficacy of the active ingredient. In 2015, the drug held a market share of 9.52%. The introduction of the FDC lovastatin 20 mg + niacin ER 500 mg led to a decrease in the use of the FDC amloidipine 5 mg + atorvastatin 10 mg and reduced its market share from 38.44% to 27.30%. The FDC lovastatin 20 mg + niacin ER 500 mg is particularly useful for patients who must increase their HDL-C and reduce LDL-C level. Niacin is a B-complex vitamin that affects multiple lipoproteins and is currently the most effective drug for increasing HDL-C level.

The overall consumption of the analysed FDCs increased, which affected the use of their individual constituents. Although the consumption of simvastatin 40 mg decreased as its market share dropped, ezetimibe 10 mg use increased despite a drop in its market share. The combination of ezetimibe with a statin may reduce LDL-C by ≥20% and is effective for patients with combined hyperlipidaemia and low HDL-C level. Lovastatin 20 mg + niacin ER 500 mg is not prescribed or administered individually, which may account for the increase in the use of this particular FDC.

Similar to statins, the usage rate of both single and FDC cholesterol-lowering products increased in 2015. Statins supplemented with ezetimibe are highly effective in improving blood lipid profiles. However, in Taiwan, the National Health Insurance regulations do not require the reduction or discontinuation of these drugs after the treatment target has been attained. Physicians may appropriately manage patients’ conditions and integrate lifelong disease prevention in the treatment regimen. Lifelong disease prevention is crucial in therapeutic management, and the International Atherosclerosis Society recommends that lipid-lowering therapies include long-term extrapolation of the risk of a cardiovascular event by 80 years of age.

CONCLUSIONS

Overall, our results show the increased use of fixed-dose, high-intensity and moderate-intensity monotherapy and combined therapy statins in high-risk groups, which matches the recommendations of the 2013 ACC/AHA guidelines. These changes were associated with increased effectiveness and reduced adverse effects to have an effect on patients.

REFERENCES

1 Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American heart association Task force on practice guidelines. J Am Coll Cardiol 2013;2014:2889–934.
2 Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association Task force on practice guidelines. Circulation 2013;2014:ST–45.
3 Department of Statistics, Ministry of Health and Welfare. Taiwan’s leading causes of death in 2016. Available: https://www.mohw.gov.tw/cp-115-33347-2.html [Accessed 26 Mar 2019].
4 LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35.
5 Rosenson RS. Statins: can the new generation make an impression? Expert Opin Emerg Drugs 2004;9:269–79.
6 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–97.
7 Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 26 randomised trials. Lancet 2010;376:1670–81.
8 Steen DL, Khan L, Beck KC, et al. Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: insights from a large US managed-care population. Clin Cardiol 2017;40:155–62.
9 Tran JN, Caglar T, Stockl KM, et al. Impact of the new ACC/AHA guidelines on the treatment of high blood cholesterol in a managed care setting. Am Heal Drug Benefits 2017;4:430–43.
10 Rosenson RS, Farkouh ME, Mefford M, et al. Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014. J Am Coll Cardiol 2017;69:2696–706.
11 Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–90.
12 Central Health Insurance Agency, Ministry of Health and Welfare. Announcement on revised lipid-lowering drug payment regulations. Available: http://www.nhi.gov.tw/epaper/itemDetail.aspx?DataID=3364&IsWebData=0&ItemTypeId=2&PaperIds=293&PicId [Accessed 26 Mar 2019].
13 Sisson EM, Pamulapati L, Buchheit JD, et al. Evolving role of non-statin therapy for the management of dyslipidemia and cardiovascular risk reduction: past, present, and future. Pharmacotherapy 2018;38:164–71.
14 Leppänen KE, Khan L, Beck KC, et al. Management of hypertriglyceridermia - a review. World J Diabetes 2016;7:74–88.
15 Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. Acc expert consensus decision pathway on the role of Non-Statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease: a report of the American College of cardiology Task force on clinical expert consensus documents. J Am Coll Cardiol 2016;2016:92–125.
16 Hsieh H-C, Hsu JC, Lu CY. 10-year trends in statin utilization. J Cardiol 2018;2018:1–9.
17 European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of cardiology (ESC) and the European atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–818.
18 Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58.
19 Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151–7.
20 Recto CS, Acosta S, Doba A. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. Clin Cardiol 2000;23:682–8.
21 Wu C-C, Sy R, Tangphaichitr V, et al. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol-a multinational, multicenter, double-blind study. J Formos Med Assoc 2002;101:478–87.
22 Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330–41.
23 da Silva PM. Are all statins the same? focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs 2011;11:93–107.
24 Masana L. Pitavastatin - from clinical trials to clinical practice. Atheroscler Suppl 2010;11:15–22.
25 Takase O, Kerndt C, Cassagnol M. Simvastatin. Treasure Island, FL, 2020.
26 Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol 2009;20:505–11.
27 Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens 2006;8:35–41.
28 Xavier HT. [Drug combinations: statins and fibrates]. Arq Bras Cardiol 2005;85:34–5.
29 Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinoi Metab Clin North Am 2009;38:79–97.
30 Cohen DE. Balancing cholesterol synthesis and absorption in the gastrointestinal tract. Arq Bras Cardiol 2018;100:267–78.
31 Grigole L, Notara GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag 2008;4:267–78.
32 Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR® trial). Am J Cardiol 2003;92:152–60.
33 Insull W, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121–7.
34 Kurogi K, Sugiyama S, Sakamoto K, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study. J Cardiol 2013;62:87–94.
35 Klimek M, Wang S, Ogunkannmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T 2009;34:313–27.
36 Crouse JR. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 1996;7:321–6.
37 Farrer S. Beyond statins: emerging evidence for hdl-increasing therapies and diet in treating cardiovascular disease. Adv Prev Med 2018;2018:1–9.
38 Hamilton-Craig I, Colquhoun D, Kostner K, et al. Lipid-modifying therapy in the elderly. Vasc Health Risk Manag 2015;11:251–63.